Telix Pharmaceuticals Limited announced new leadership appointments as part of an internal reorganization to align its operations across four business units, reflecting its focus as a therapeutics-led radiopharmaceutical company committed to precision oncology. The updated business model comprises: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech) and Telix Manufacturing Solutions (TMS). As part of this initiative, the Company announces three leadership changes: Richard Valeix, Chief Executive Officer, Telix Therapeutics (formerly Group Chief Commercial Officer)[1], leading the Company's therapeutic pipeline commercialisation and business development; Kevin Richardson, Chief Executive Officer, Telix Precision Medicine (formerly Chief Executive Officer, Americas), leading the development of the Company's diagnostics, global marketing and commercial operations in the U.S. and Canada; Raphael Ortiz, Chief Executive Officer, Telix International, leading the "rest of world" commercial operations for Europe, Middle East and Africa (EMEA), Asia Pacific (APAC) and Latin America regions (formerly Chief Executive Officer, EMEA & APAC).
Darren Patti remains Group Chief Operating Officer, with leadership responsibility for Telix's internal manufacturing operations, including the operations of ARTMS, IsoTherapeutics and Optimal Tracers, which sit under the TMS umbrella.
